Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey.
| Revenue (TTM) | 158,000 |
| Gross Profit (TTM) | $-278.65M |
| EBITDA | $-322.43M |
| Operating Margin | -366468.00% |
| Return on Equity | -43.90% |
| Return on Assets | -27.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $9.10 |
| Price-to-Book | 4.32 |
| Price-to-Sales (TTM) | 19721.85 |
| EV/Revenue | 15047.18 |
| EV/EBITDA | -17.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -97.00% |
| Shares Outstanding | $78.53M |
| Float | $73.02M |
| % Insiders | 0.27% |
| % Institutions | 110.26% |
Volatility is currently contracting
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine whether Celldex Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript
Celldex Therapeutics NASDAQ: CLDX said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria studies.
Celldex Therapeutics said on Tuesday it would discontinue the development of its experimental drug for a skin disease after it failed to meet the main goal and key secondary goals in a mid-stage study, sending its shares down over 7% in extended trading.
HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company's Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis (PN), a chronic skin disease that causes hard, intensely itchy lumps/nodules to form on the skin. The primary endpoint of the study, the proportion of patients who achieve a four point or greater improvement in WI-NRS (Worst Itch Numeric Rating Scale) from baseline to Week 12, and key secondary endpoints were not met.
HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire in 2027. Mr. Martin has served as the Company's Chief Financial Officer since 2017 and as a member of the Celldex finance team since April 2009. Celldex has initiated a search for a new Chief Financial Officer, and Mr. Martin will remain as the Company's CFO through March of 2027, to support a smooth transition.
-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that three presentations from the barzolvolimab and CDX-622 programs will be shared at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress being held in Istanbul, Türkiye, on June 12-15, 2026.
The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CLDX and any ticker you trade — then tracks every position and per-strategy win rate.
